News and Media

Distant leader in the treatment of cardiovascular disease among all drug manufacturers present on the Bulgarian market with market share 10.57% in 2017 and 11.39% for the first half of 2018 (Source:  IQVIA/IMS Health), with deep potential for further growth following the market entry of newly developed and introduced medicaments. Tchaikapharma 7TH

The Financial Supervision Commission (FSC) registered the shares issued by Tchaikapharma High Quality Medicines Inc. as a result of an increase of the company’s capital with a view to trading on a regulated securities market. This is evident from the regulator’s decisions at the meeting held on the 23rd of August. The equity issue amounts […]

The current capital of the pharmaceutical company is BGN 64.3 million. Tchaikapharma High Quality Medicines Inc. announced that following the entry in the Commercial Register the capital of the company was increased by BGN 7.7 million, the announcement came through the BSE-Sofia. The current capital of the pharmaceutical company is BGN 64.3 million, divided into […]

The voted dividend for 2016  is 7 700 000. The amount of the capital after the increase is BGN 64 300 000. On June 8, 2017, the Annual General Meeting of Shareholders (GMS) of Tchaikapharma High Quality Medicines Inc. was held with the required quorum. A total of 56,562,089 shares were represented – all with […]

On the basis of art.27, par.1. it. 2 of the Ordinance No. 2 of the Financial Supervision Commission (FSC), we notify the following circumstances relating to Tchaikapharma High Quality Medicines Inc., which constitute “internal information” within the meaning of Art. 4 of the Law Against Market Abuse with Financial Instruments and Ordinance No. 2 of […]